Program Schedule

An International, Multicenter, Retrospective Study of Nosocomial Pneumonia due to Pseudomonas aeruginosa

Session: Poster Abstract Session: Multidrug-resistant Organisms: Epidemiology and Prevention
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
  • 339_Micek_IDWEEK2014.pdf (487.6 kB)
  • Background:

    Nosocomial pneumonia is a prevalent hospital-acquired infection associated with increased morbidity and mortality.  The purpose of this study is to describe the clinical characteristics, antibiotic resistance patterns, and outcomes of patients with Pseudomonas aeruginosa nosocomial pneumonia.

    Methods: Retrospective, hospital-based medical record abstraction. Records were obtained from 10 hospitals throughout the United States and Europe.

    Results: Among the 396 patients included in the study, ventilator-associated (50%) was the most common classification followed by hospital-acquired (26%), and healthcare-associated pneumonia (24%).  Concomitant bacteremia occurred in 23% of cases and septic shock complicating pneumonia occurred in 63% of patients.  Antibiotic resistance was common across all drug classes: aminoglycosides (27%), antipseudomonal (AP) penicillins + β-lactamase inhibitors (29%), AP carbapenems (36%), AP cephalosporins (26%), and ciprofloxacin (34%).  Multidrug resistance (MDR) was present in 31% of pneumonia cases.  Appropriate initial antibiotic therapy was prescribed in 60% of patients.  In-hospital mortality occurred in 42% of patients.  In-hospital mortality was significantly greater in patients with an MDR isolate compared to non-MDR isolates (51% v. 33%, p = 0.001).  The median (IQR) time-to-death was 12 (4, 25) days.  Median (IQR) hospital length of stay was 30 (17, 56) days and was significantly longer in survivors compared to nonsurvivors (median 36 v. 27 days, p = 0.02). 


    Pseudomonas aeruginosa nosocomial pneumonia is frequently complicated by septic shock and has high in-hospital mortality rate.  Antibiotics resistance is common and likely contributes to an unacceptably low rate of initial appropriate antibiotic therapy.

    Scott Micek, PharmD, Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, MO, Richard Wunderink, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, Catherine Chen, MD, Washington University School of Medicine, St. Louis, MO, Jordi Rello, MD, Hospital Vall DíHebron, Barcelona, Spain, Jean E. Chastre, MD, Reanimation Medicale, Pitie-Salpetriere Hospital, Paris, France, Vandana Menon, MD, Cubist Pharmaceuticals, Inc, Lexington, MA, Marin Kollef, MD, Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO and Investigators of the International Study of Nosocomial Pneumonia due to Pseudomonas aeruginosa


    S. Micek, Cubist Pharmaceuticals: Grant Investigator, Research grant

    R. Wunderink, Genentech: Consultant, Consulting fee
    Crucell/Janssen/J&J: Consultant, Consulting fee

    C. Chen, None

    J. Rello, Cubist: Grant Investigator, Research grant

    J. E. Chastre, Cubist: Grant Investigator, Research grant

    V. Menon, None

    M. Kollef, Tetraphase: Grant Investigator, Research support

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, All Rights Reserved.

    Follow IDWeek